Q-and-A: Merck's efforts to address neurological diseases

10/15/2007 | M.I.T. Technology Review

David Michelson, Merck's vice president of clinical neuroscience and ophthalmology, said in an interview the company is developing biologics and vaccines to prevent Alzheimer's and working to identify markers for Alzheimer's and schizophrenia. Michelson said the firm also is conducting trials on a drug-coated helical intraocular implant device for treating patients with diabetic macular edema.

View Full Article in:

M.I.T. Technology Review

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX